Cargando…

Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study

OBJECTIVE: To identify a suitable dosing regimen of the CD22-targeted monoclonal antibody epratuzumab in adults with moderately to severely active systemic lupus erythematosus (SLE). METHODS: A phase IIb, multicentre, randomised controlled study (NCT00624351) was conducted with 227 patients (37–39 p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wallace, Daniel J, Kalunian, Kenneth, Petri, Michelle A, Strand, Vibeke, Houssiau, Frederic A, Pike, Marilyn, Kilgallen, Brian, Bongardt, Sabine, Barry, Anna, Kelley, Lexy, Gordon, Caroline
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2014
Materias:	Clinical and Epidemiological Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3888603/ https://www.ncbi.nlm.nih.gov/pubmed/23313811 http://dx.doi.org/10.1136/annrheumdis-2012-202760

Ejemplares similares

Epratuzumab for patients with moderate to severe flaring SLE: health-related quality of life outcomes and corticosteroid use in the randomized controlled ALLEVIATE trials and extension study SL0006
por: Strand, Vibeke, et al.
Publicado: (2014)

Data Quality Challenges in Systemic Lupus Erythematosus Trials: How Can This Be Optimized?
por: Pike, Marilyn C., et al.
Publicado: (2012)

Profile of epratuzumab and its potential in the treatment of systemic lupus erythematosus
por: Al Rayes, Hanan, et al.
Publicado: (2014)

Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus
por: Dörner, Thomas, et al.
Publicado: (2006)

Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double‐Blind, Placebo‐Controlled Trials
por: Clowse, Megan E. B., et al.
Publicado: (2017)

Correction: Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus
por: Dörner, Thomas, et al.
Publicado: (2008)

Epratuzumab targeting of CD22 affects adhesion molecule expression and migration of B-cells in systemic lupus erythematosus
por: Daridon, Capucine, et al.
Publicado: (2010)

The double emblem
Publicado: (1982)

An Emblem of Decay
Publicado: (1921)

Emblems and Symbols
por: Towner, Ausburn
Publicado: (1884)

Efficacy of Epratuzumab, an Anti‐CD22 Monoclonal IgG Antibody, in Systemic Lupus Erythematosus Patients With Associated Sjögren's Syndrome: Post Hoc Analyses From the EMBODY Trials
por: Gottenberg, Jacques‐Eric, et al.
Publicado: (2018)

Gold nanotheranostics: future emblem of cancer nanomedicine
por: Navyatha, Bankuru, et al.
Publicado: (2021)

Emblem and state in the classic Maya Lowlands : an epigraphic approach to territorial organization
por: Marcus, Joyce
Publicado: (1976)

Phase 3, multicentre, randomised, placebo-controlled study evaluating the efficacy and safety of ustekinumab in patients with systemic lupus erythematosus
por: van Vollenhoven, Ronald F, et al.
Publicado: (2022)

Fosdagrocorat (PF-04171327) versus prednisone or placebo in rheumatoid arthritis: a randomised, double-blind, multicentre, phase IIb study
por: Buttgereit, Frank, et al.
Publicado: (2019)

Emblems and typographical imprints of XXth century scientific publishers
por: RODRÍGUEZ VALCÁRCEL, JOSÉ ANTONIO
Publicado: (2006)

Swiss flag or Red Cross emblem: why the confusion?
por: Stahel, Philip F
Publicado: (2013)

Evaluating duration of response to treatment in systemic lupus erythematosus clinical trials
por: Kim, Mimi, et al.
Publicado: (2018)

Michael Maier's Atalanta Fugiens: Sources of an Alchemical Book of Emblems
por: Pagel, Walter
Publicado: (1973)

'Caduceus'—Or the Significance of Serpents as Emblem of Art of Healing and the Snake Worship
por: Chowhan, J. S.
Publicado: (1949)

Emblem Gestures Improve Perception and Evaluation of Non-native Speech
por: Billot-Vasquez, Kiana, et al.
Publicado: (2020)

Complement Activation in Patients With Probable Systemic Lupus Erythematosus and Ability to Predict Progression to American College of Rheumatology–Classified Systemic Lupus Erythematosus
por: Ramsey‐Goldman, Rosalind, et al.
Publicado: (2019)

Impact of belimumab on patient-reported outcomes in systemic lupus erythematosus: review of clinical studies
por: Bangert, Elvira, et al.
Publicado: (2019)

Fc γ R IIB gene polymorphisms in Indian systemic lupus erythematosus (SLE) patients
por: Pradhan, Vandana, et al.
Publicado: (2011)

Clinical, laboratory and health-related quality of life correlates of Systemic Lupus Erythematosus Responder Index response: a post hoc analysis of the phase 3 belimumab trials
por: Furie, Richard, et al.
Publicado: (2014)

Systemic lupus erythematosus with multicentric reticulohistiocytosis: A case report
por: Liu, Ping-Ping, et al.
Publicado: (2023)

Le Globe de la science: un emblème pour le CERN
Publicado: (2006)

Efficacy and Safety of Atacicept in Patients With Systemic Lupus Erythematosus: Results of a Twenty‐Four–Week, Multicenter, Randomized, Double‐Blind, Placebo‐Controlled, Parallel‐Arm, Phase IIb Study
por: Merrill, Joan T., et al.
Publicado: (2018)

Infection-related hospitalisation in young adults with systemic lupus erythematosus: data from the National Inpatient Sample
por: Dhital, Rashmi, et al.
Publicado: (2023)

Unmet medical needs in systemic lupus erythematosus
por: Lateef, Aisha, et al.
Publicado: (2012)

Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial
por: Wallace, Daniel J, et al.
Publicado: (2017)

Lupuzor/P140 peptide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled phase IIb clinical trial
por: Zimmer, Robert, et al.
Publicado: (2013)

Measurement properties of selected patient-reported outcome measures for use in randomised controlled trials in patients with systemic lupus erythematosus: a systematic review
por: Strand, Vibeke, et al.
Publicado: (2020)

The modular cardiac rhythm management system: the EMPOWER leadless pacemaker and the EMBLEM subcutaneous ICD
por: Tjong, F. V. Y., et al.
Publicado: (2018)

A norming study of high-quality video clips of pantomimes, emblems, and meaningless gestures
por: Agostini, Beatrice, et al.
Publicado: (2018)

Long‐Term Impact of Belimumab on Health‐Related Quality of Life and Fatigue in Patients With Systemic Lupus Erythematosus: Six Years of Treatment
por: Strand, Vibeke, et al.
Publicado: (2019)

Immunosuppressant use and hospitalisations in adult patients with systemic lupus erythematosus admitted to a tertiary academic medical centre
por: Anastasiou, Christine, et al.
Publicado: (2018)

Work disability, lost productivity and associated risk factors in patients diagnosed with systemic lupus erythematosus
por: Utset, Tammy O, et al.
Publicado: (2015)

Very Late-Onset Systemic Lupus Erythematosus as Unusual Cause of Reversible Functional and Cognitive Impairments in an Octogenarian Patient
por: de Montjoye, Stéphanie, et al.
Publicado: (2020)

Extensive crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in human lymphoma cells
por: Chang, Chien-Hsing, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_u40litmdrirom723qlnr94qhhg